Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

by B2i | Dec 6, 2022 | Press Releases

ROCKVILLE, Md., Dec. 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...

Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update

by B2i | Nov 15, 2022 | Press Releases

ROCKVILLE, Md., Nov. 15, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study

by B2i | Nov 3, 2022 | Press Releases

ROCKVILLE, Md., Nov. 3, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its...

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

by B2i | Nov 2, 2022 | Press Releases

ROCKVILLE, Md., Nov. 1, 2022 –Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...

Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine

by B2i | Sep 20, 2022 | Press Releases

Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md., Sept. 20, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of...